This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Aprepitant shows a broad-spectrum anticancer effect against many tumor types.
Why it matters
Repurposing Aprepitant could provide a new strategy for cancer treatment, potentially improving patient quality of life. This approach may lead to more effective therapies for various cancers.
How the study worked
This is a review article summarizing existing research on NK-1R antagonists and their potential as anticancer drugs.
What this study cannot tell us
As a review, it does not present original experimental data; further clinical trials are needed to validate findings.
Read the original research
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
International journal of molecular sciences, 24(21)
Citation
Coveñas, Rafael; Rodríguez, Francisco D; Robinson, Prema; Muñoz, Miguel. (2023). The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.. International journal of molecular sciences, 24(21). https://doi.org/10.3390/ijms242115936